PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Poly(ADP-ribose) polymerase (PARP) inhibitors leverage synthetic lethality to target homologous recombination (HR)-deficient cancers.
• BRCA mutations are key drivers in certain cancers, influencing sensitivity to PARP inhibitors.
• Ovarian cancer (OC) is a primary focus for PARP inhibitor development, with olaparib already approved for advanced BRCA-mutated cases.

Purpose of the Study:

• To review the role of BRCA mutations in cancer development and PARP inhibitor efficacy.
• To summarize the clinical development and application of PARP inhibitors in ovarian cancer treatment.
• To explore the potential of PARP inhibitors beyond BRCA mutations in HR-deficient cancers.

Main Methods:

• Review of clinical trial data and scientific literature on PARP inhibitors and BRCA mutations in ovarian cancer.
• Analysis of olaparib's clinical investigation and approval status.
• Examination of ongoing research into broader applications and predictive biomarkers for PARP inhibitor therapy.

Main Results:

• PARP inhibitors, particularly olaparib, demonstrate durable anti-tumor activity in BRCA-mutated advanced ovarian cancer, especially in platinum-sensitive disease.
• These agents are generally well-tolerated, but require careful monitoring for moderate and late-onset toxicities.
• Combination therapies with chemotherapy and novel agents are under investigation to enhance anti-tumor effects.

Conclusions:

• PARP inhibitors are effective in BRCA-mutated ovarian cancer and are being expanded to other HR-deficient malignancies.
• Defining an HR-deficiency signature may predict sensitivity in sporadic ovarian cancer.
• Continued evaluation of safety and efficacy in various settings is crucial.